JCN Newswire Biologics License Application for Subcutaneous Formulation of “LEQEMBI(R)” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China 6 1 月, 2026 TOKYO and CAMBRIDGE, Mass., Jan […]
